Recurrent Neuroblastoma Recruiting Phase 2 Trials for Dasatinib (DB01254)

Also known as: Neuroblastoma Recurrent

IndicationStatusPhase
DBCOND0028756 (Recurrent Neuroblastoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01467986Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk NeuroblastomaTreatment